{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-033591","form_type":"8-K","ticker":"CNTN","cik":"0001861657","company_name":"Canton Strategic Holdings, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.863293+00:00","generated_at":"2026-06-10T09:20:56.859189+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Hillstream BioPharma changes name to Tharimmune, progress on acquiring TH104, plans Phase 1 trial in Q4","bullets":["Name change to Tharimmune effective Sep 25, 2023; new ticker THAR on Nasdaq.","Progressing towards acquiring clinical-stage asset TH104 with recently approved IND.","Expects to close TH104 acquisition in Q4 2023 and launch/complete Phase 1 PK trial by year-end.","TH104 targets chronic pruritis in primary biliary cholangitis; prior ex-US trials showed reliable bioavailability."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-033591","json":"https://secwatch.observer/filing/0001493152-23-033591.json","markdown":"https://secwatch.observer/filing/0001493152-23-033591.md","text":"https://secwatch.observer/filing/0001493152-23-033591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223033591/0001493152-23-033591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223033591/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:20:56.859189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcf40f5bbe8283a8e0494cd20b2bd52ac98f91ad","claim":"Canton Strategic Holdings, Inc.: Company changed its name from Hillstream BioPharma, Inc. to Tharimmune, Inc. via a Certificate of Amendment to its Certificate of Incorporation (effective 2023-09-25).","evidence_excerpt":"On September 21, 2023, Hillstream BioPharma, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware pursuant to which it changed its name to Tharimmune, Inc. effective as of September 25, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861657/000149315223033591/0001493152-23-033591-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-09-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}